Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.34 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18398621 | 0.83 | CYP2D6 (0.33) | L3MBTL3MEN1KMT2AL3MBTL1 | |
| SCHEMBL2148090 | 0.81 | ALDH1A1 (0.37) | SLC18A3MBTD1L3MBTL3MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6607826 | 0.79 | ALDH1A1 (0.40) | SLC18A3MBTD1L3MBTL3MEN1KMT2A | |
| SCHEMBL6120938 | 0.79 | SLC18A3 (0.34) | SLC18A3MBTD1L3MBTL3 | |
| SCHEMBL21068062 | 0.79 | SLC18A3 (0.34) | SLC18A3 | |
| SCHEMBL13740202 | 0.79 | NOS2 (0.34) | SLC18A3 | |
| SCHEMBL277795 | 0.77 | MEN1 (0.35) | MEN1APEX1KMT2ATDP1L3MBTL1 | |
| SCHEMBL2148202 | 0.76 | ALDH1A1 (0.39) | MBTD1L3MBTL3MEN1KMT2AL3MBTL1 | |
| SCHEMBL4020631 | 0.72 | SLC18A3 (0.34) | SLC18A3MEN1KMT2A | |
| SCHEMBL3453171 | 0.71 | PREP (0.41) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018136887-A1 | COMPOUNDS | TESARO, INC. (US) | 2018-07-26 | — | — | WO | claimed |
| US-12403139-B2 | Methods and compositions for prevention and treatment of cardiac hypertrophy | UNIVERSITY OF HAWAII (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240189303-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | UNIVERSITY OF HAWAII | 2024-06-13 | — | — | US | disclosed |
| US-20190192508-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | UNIV HAWAII (US) | 2019-06-27 | — | — | US | disclosed |
| US-10137123-B2 | Methods and compositions for prevention and treatment of cardiac hypertrophy | UNIVERSITY OF HAWAII (US) | 2018-11-27 | — | — | US | disclosed |
| WO-2018136887-A1 | COMPOUNDS | TESARO, INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| US-20170231982-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | UNIVERSITY OF HAWAII | 2017-08-17 | — | — | US | disclosed |
| US-20150352105-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-12-10 | — | — | US | disclosed |
| US-9084786-B2 | Methods and compositions for prevention and treatmentof cardiac hypertrophy | UNIVERSITY OF HAWAII (US) | 2015-07-21 | — | — | US | disclosed |
| US-20130274271-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENTOF CARDIAC HYPERTROPHY | UNIVERSITY OF HAWAII (US) | 2013-10-17 | — | — | US | disclosed |
| WO-2012152854-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-11-15 | — | — | WO | disclosed |
| US-20110190503-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICAL NV | 2011-08-04 | — | — | US | disclosed |
| US-20110159563-A1 | Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICAL NV | 2011-06-30 | — | — | US | disclosed |
| US-7939527-B2 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-10 | — | — | US | disclosed |
| US-20100029657-A1 | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| US-20090258854-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258854-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | LTA4H, LTC4S, LTB4R2 | SLC18A3 2328/4885MBTD1 1874/4885L3MBTL3 2302/4885 |
| US-20110159563-A1 | Thyazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | LTA4H, LTC4S, LTB4R2 | SLC18A3 1857/4885MBTD1 2374/4885L3MBTL3 2045/4885 |
| US-20110190503-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | LTA4H, LTC4S, LTB4R2 | SLC18A3 2328/4885MBTD1 1874/4885L3MBTL3 2302/4885 |
| US-20100029657-A1 | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof | BRAF, RAF1, ARAF | SLC18A3 4756/4885MBTD1 2458/4885L3MBTL3 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.